Source-grounded facts extracted from Crinetics Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2026-06-18 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 91,657,992 2,698,538 2,629,874 5,044,011”
Crinetics Pharmaceuticals, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.
“The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were: Votes For Votes Against Abstentions 101,675,974 341,727 12,714”
Crinetics Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. at the 2026-06-18 meeting.
“The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Caren Deardorf 73,454,076 23,532,328 5,044,011 Weston Nichols, Ph.D. 90,208,564 6,777,840 5,044,011 Stephanie S. Okey, M.S. 72,225,313 24,761,091 5,044,011”
Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $10.7 million. Guidance reaffirmed.
“ACTH antagonist, atumelnant, in a broad population including patients with both Cushing’s disease and ectopic ACTH syndrome. First Quarter 2026 Financial Results: • Revenue was $10.7 million for the quarter ended March 31, 2026, compared to $0.4 million for the same period in 2025. Revenue for the quarter ended March 31, 2026 includes $10.3 million in net product”
Crinetics Pharmaceuticals, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“(b) Appointment of New Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee approved the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s new independent registered public accounting firm for the fiscal year ended December 31, 2026.”
Crinetics Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its auditor.
“(a) Dismissal of Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee (the "Audit Committee") of the Board of Directors of Crinetics Pharmaceuticals, Inc. (the "Company") approved the dismissal of BDO USA, P.C. ("BDO") as the Company’s independent registered public accounting firm.”
Marc Wilson resigned as other at Crinetics Pharmaceuticals, Inc..
“pursuant to which Mr. Wilson resigned as an employee of the Company, effective April 1, 2025”
Tobin "Toby" Schilke was appointed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..
“On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.”
James Hassard departed as Chief Operating Officer at Crinetics Pharmaceuticals, Inc..
“James Hassard ceased serving as the Chief Operating Officer of the Company, effective October 14, 2024.”
James Hassard departed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..
“On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.”
Marc Wilson departed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..
“On August 5, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company.”
Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million, net income $66.9 million.
“of $5.6 million. • Net loss for the three months ended March 31, 2024, was $66.9 million, compared to a net loss of $46.0 million for the same period in 2023. • Revenues were$0.6 million for the three months ended March 31, 2024, compared to $2.7 million for the same period in 2023. Revenues were derived from licensing arrangements for our paltusotine product”
Crinetics Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at aggregate gross proceeds from the Private Placement of approximately $350 million (effective 2024-02-27).
“On February 27, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 8,333,334 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $ 42.00 per share.”
Crinetics Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $4.0 million, net income net loss of $214.5 million.
“ended December 31, 2022 and $1.0 million for the year ended December 31, 2022. This loss was derived from the company’s investment in Radionetics Oncology, Inc. • Revenues were $4.0 million for the full year ended December 31, 2023, compared to $4.7 million for the same period in 2022. There were no revenues for the three months ended December 31, 2023, compared to”
Crinetics Pharmaceuticals, Inc.: Amended bylaws to address universal proxy rules, enhance stockholder nomination and proposal disclosure requirements, and require a non-white proxy card color for stockholders soliciting proxies (effective 2023-12-06).
“On December 6, 2023, the Board of Directors (the “Board”) of Crinetics Pharmaceuticals, Inc. (the “Company”) adopted amendments to the Company’s amended and restated bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.”
Crinetics Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $0.3 million, net income $57.5 million.
“$3.2 million. • Net loss for the three months ended September 30, 2023, was $57.5 million, compared to a net loss of $41.9 million for the same period in 2022. • Revenues were $0.3 million for the three months ended September 30, 2023, compared to $0.5 million for the same period in 2022. Revenues in both periods were primarily derived from the paltusotine”
Crinetics Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million, net income Net loss of $51.0 million.
“of $2.7 million. • Net loss for the three months ended June 30, 2023, was $51.0 million, compared to a net loss of $42.4 million for the same period in 2022. • Revenues were $1.0 million for the three months ended June 30, 2023, compared to $0.4 million for the same period in 2022. Revenues in both periods were primarily derived from the paltusotine licensing”
Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, regarding whether the stockholder vote to approve the compensation of the Company's named executive officers should occur every one, two or three years at the 2023-06-16 meeting.
“The Company’s stockholders approved, on an advisory basis, that the compensation of the Company’s named executive officers should occur every one, two or three years. The results of such vote were: Votes For 1 Yr. Votes for 2 Yr. Votes for 3 Yr. Abstentions Broker Non-Votes 41,312,125 1,577 403,696 4,570,396 2,048,473”
Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-16 meeting.
“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 45,092,585 1,192,212 2,997 2,048,473”
Crinetics Pharmaceuticals, Inc. shareholders approved Ratification of selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-16 meeting.
“The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 48,326,036 3,916 6,315 0”
Crinetics Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to the Board of Directors for three year terms to expire at the 2026 annual meeting of stockholders at the 2023-06-16 meeting.
“The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three year terms to expire at the 2026 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Caren Deardorf 37,044,248 9,243,546 2,048,473 Weston Nichols, Ph.D. 44,252,003 2,035,791 2,048,473 Stephanie S. Okey, M.S. 36,802,418 9,485,376 2,048,473”
Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $2.7 million, net income Net loss of $46.0 million.
“for the three months ended March 31, 2023, compared to $8.7 million for the same period in 2022. The increase was primarily attributable to an increase in personnel costs of $2.7 million and an increase in other corporate expenditures of $0.8 million. • Net loss for the three months ended March 31, 2023 was $46.0 million, compared to a net loss of $34.6 million”
Crinetics Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.
“SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.”
Crinetics Pharmaceuticals, Inc. reported financial results for the fourth quarter ended December 31, 2022.
“SAN DIEGO – February 28, 2023 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.”
Crinetics Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.5 million, net income $41.9 million.
“$3.0 million. • Net loss for the three months ended September 30, 2022, was $41.9 million, compared to a net loss of $27.9 million for the same period in 2021. • Revenues were $0.5 million for the three months ended September 30, 2022, consisting of license revenue recognized from the license agreement entered into with Sanwa Kagaku Kenkyusho Co., Ltd. in February”
Dana Pizzuti was appointed as Chief Development Officer at Crinetics Pharmaceuticals, Inc..
“On October 3, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Dana Pizzuti, M.D. as the Company’s Chief Development Officer, which was effective as of September 30, 2022.”
Ajay Madan resigned as Chief Development Officer at Crinetics Pharmaceuticals, Inc..
“On March 21, 2022, Ajay Madan, Ph.D., provided notice to the Chief Executive Officer of Crinetics Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Development Officer of the Company, to be effective April 1, 2022.”
Caren Deardorf was appointed as Director at Crinetics Pharmaceuticals, Inc..
“the Board approved an increase in its authorized size from seven members to eight members and appointed Caren Deardorf to fill the vacancy created by such increase and serve as a Class II director”
James Hassard was appointed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..
“On March 1, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of James Hassard as the Company’s Chief Commercial Officer, which was effective as of February 28, 2022.”
Rogério Vivaldi Coelho was appointed as Class I Director at Crinetics Pharmaceuticals, Inc..
“the Board approved an increase in its authorized size from six members to seven members and appointed Rogério Vivaldi Coelho, M.D., M.B.A. to fill the vacancy created by such increase and serve as a Class I director”
Jeff Knight was appointed as Chief Operating Officer at Crinetics Pharmaceuticals, Inc..
“On September 2, 2021, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Jeff Knight as the Company’s Chief Operating Officer, which was effective as of August 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.